Johnson & Johnson plans to separate its orthopedics segment into its own business within 18 to 24 months, according to an Oct. 14 news release.
The company said it expects the move to improve top-line growth and operating margins in the orthopedics unit, which generated about $9.2 billion in sales in fiscal 2024. The business is to be named DePuy Synthes.
“Upon completion of the planned separation, DePuy Synthes would be the largest, most comprehensive orthopaedics-focused company, with leading market share positions across major product categories,” the release said.
In late 2021, J&J announced it would split itself into two companies, one for consumer health products and another for pharmaceuticals and medical devices.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
